

Double-blind peer review submissions: write DBPR and your manuscript number here

Corresponding author(s): instead of author names.

Last updated by author(s): YYYY-MM-DD

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

Statistics					
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Metho	ods section.				
Confirmed					
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measuremental group/condition, given as a discrete number and unit of measuremental group/condition, given as a discrete number and unit of measuremental group/condition, given as a discrete number and unit of measuremental group/condition, given as a discrete number and unit of measuremental group/condition, given as a discrete number and unit of measuremental group/condition, given as a discrete number and unit of measuremental group/condition, given as a discrete number and unit of measuremental group/condition, given as a discrete number and unit of measuremental group/condition, given as a discrete number and unit of measuremental group/condition and given group	ent				
A statement on whether measurements were taken from distinct samples or whether the same sample was measur	ed repeatedly				
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.					
A description of all covariates tested					
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons	S				
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)					
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom a <i>Give P values as exact values whenever suitable.</i>	nd <i>P</i> value noted				
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings					
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated					
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.					
Software and code					
Policy information about <u>availability of computer code</u>					
Data collection A mix of publicly available data and proprietary data obtained via DUAs and a primary survey. No special software The online survey is deployed via two vendors (see description in the article).	e is used to collect data.				
Data analysis SAS is used to analyze direct costs; STATA is used to analyze indirect costs.					
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.					
Data					
Policy information about availability of data					

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Claims data can be obtained via DUAs with various vendors (e.g., CMS, Optum). Publicly available data (Medical expenditure panel survey) can be downloaded online. Survey data are proprietary and not publicly available.

Please select the one	below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the	document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Behaviour	ral & social sciences study design
All studies must disclo	ose on these points even when the disclosure is negative.
Study description	Persons with Parkinson's disease have higher medical care needs, premature work cessation, often miss work, and require assistance from paid and unpaid care partners, leading to significant direct and indirect economic costs. This study provides a comprehensive analysis of the economic burdens of PD in the U.S. (2017) and projections for the next two decades.
Research sample	Claims data: PD identified based on the ICD-9 /ICD-10 codes. ICD-9/ICD-10: 332.0/G20, secondary Parkinsonism (332.1/G21), dementia with Lewy bodies [DLB] (331.82/G31.83), striatonigral degeneration (333.0/G23.1), progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski] (333.0/G23.2), degenerative disease of basal ganglia, unspecified (333.0/G90.3), and cortical basal degeneration [CBD] (331.6/G31.85) Survey: convenience sample.
Sampling strategy	Claims data: all identified cases included subject to age constraints (i.e., commercial claims are limited to age <65). Survey: convenience sample.
Data collection	Multiple data sources were used to estimate the costs of PD, including public and private administrative claims data, Medicare Current Beneficiary Survey, Medical Expenditure Panel Survey, and a primary survey (n=4,548) designed for this study.
Timing	Commercial claims are for 2016; Medicare claims - for 2015, Medical Expenditure Panel Survey (MEPS) data for 2011-2015; Medicare Current Beneficiary Survey (MCBS) for 2015
Data exclusions	na
Non-participation	na
Randomization	na

reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Ma	Materials & experimental systems Methods		thods
n/a	Involved in the study	n/a	Involved in the study
\boxtimes	Antibodies	\boxtimes	ChIP-seq
\boxtimes	Eukaryotic cell lines	\boxtimes	Flow cytometry
\boxtimes	Palaeontology	\boxtimes	MRI-based neuroimaging
\boxtimes	Animals and other organisms		
\boxtimes	Human research participants		
\boxtimes	Clinical data		